Foghorn Therapeutics Patent for Heterocyclic Compounds Treating BAF Disorders

The USPTO issued Patent No. US12590079B2 to Foghorn Therapeutics Inc. on March 31, 2026, granting exclusive rights to heterocyclic compounds and their uses for treating BAF complex-related disorders. The patent application (No. 17631791) was filed on July 31, 2020, and the granted patent contains 20 claims covering the compound compositions and methods of treatment. The CPC classifications indicate applications in cancer treatment (A61P 35/00) alongside heterocyclic chemistry classifications.

This patent grant establishes Foghorn Therapeutics' intellectual property rights in this therapeutic area, potentially affecting freedom-to-operate considerations for other companies developing similar compounds for BAF complex-related disorders. No immediate compliance actions are required by regulated entities; however, companies in the oncology or epigenetic therapy space should review this patent when assessing their IP portfolios and R&D programs.